BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18386000)

  • 1. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
    Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
    Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
    Rice J; Buchan S; Stevenson FK
    J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
    Ahn E; Kim H; Han KT; Sin JI
    Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.
    Cross RS; Malaterre J; Davenport AJ; Carpinteri S; Anderson RL; Darcy PK; Ramsay RG
    Clin Transl Immunology; 2015 Jan; 4(1):e30. PubMed ID: 25671128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
    Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
    J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
    Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
    Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.
    Leitner WW; Baker MC; Berenberg TL; Lu MC; Yannie PJ; Udey MC
    Blood; 2009 Jan; 113(1):37-45. PubMed ID: 18832136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
    Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
    Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.
    Cho HI; Celis E
    Cancer Immunol Immunother; 2012 Mar; 61(3):343-51. PubMed ID: 21915800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
    Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
    Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
    Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
    J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative DNA vaccine to break immune tolerance against tumor self-antigen.
    Kang TH; Mao CP; La V; Chen A; Hung CF; Wu TC
    Hum Gene Ther; 2013 Feb; 24(2):181-8. PubMed ID: 23268564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.